シムバスタチンは,実験的な心不全における自律神経制御を正常化する
Rainer U Pliquett1, Kurtis G Cornish, Jacob D Peuler
1Department of Physiology and Biophysics, University of Nebraska Medical Center, Omaha, NE 68198-4575, USA.
Circulation
|April 16, 2003
まとめ
スタチンは,シンバスタチンと同様に,脂質低下効果とは関係なく,交感神経系の活動とバロレフレクスの機能を正常化することによって,慢性心不全 (CHF) を改善する可能性があります. これは,CHF管理のための新しい治療アプローチを示唆しています.
科学分野:
- 心血管生理学 心血管の生理学
- 薬理学 薬理学とは
- 自律神経科学とは
背景:
- スタチン (HMG-CoA還元酵素阻害剤) は,慢性心不全 (CHF) の治療に有益であることが示されています.
- CHFにおけるスタチンの自律的機能への影響は完全に理解されていません.
- 交感性多動性を含む自律的機能障害は,CHFの特徴です.
研究 の 目的:
- CHFのウサギモデルにおける自律機能に対するシンバスタチンの影響を調査する.
- シムバスタチンが交感神経の活動とバロレフレクスの感受性に影響するかどうかを評価する.
- これらの効果が脂質を低下させる性質から独立しているかどうかを判断する.
主な方法:
- 慢性心不全 (CHF) は,ウサギで心室ペースを介して誘発されました.
- ウサギは,媒介体またはシンバスタチン (低用量または高用量) を投与された.
- 腎交感神経活動 (RSNA),血ノルエピネフリン,およびバロレフレクスの機能は意識のある動物で測定されました.
主要な成果:
- ベースラインのRSNAとノレピネフリン濃度は,CHFのウサギで上昇していた.
- 高用量シムバスタチンは,CHFのウサギのRSNAとプラズマノレピネフリンを著しく減少させた.
- シムバスタチン治療は,低血圧への反応として,心拍数のバロレフレクスの調節を正常化させた.
結論:
- スタチンの非脂質低下作用には,CHFにおける交感性アウトフローの正常化が含まれています.
- シムバスタチンは,実験的なCHFにおける自律的調節とバロレフレクスの機能を改善します.
- これらの発見は,CHFの進行を管理するための潜在的な新しい治療戦略を示唆しています.
キーワード:
非プログラム的なものです.
関連する概念動画
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...